Does METOPROLOL Cause Second primary malignancy? 42 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Second primary malignancy have been filed in association with METOPROLOL (metoprolol succinate). This represents 0.1% of all adverse event reports for METOPROLOL.
42
Reports of Second primary malignancy with METOPROLOL
0.1%
of all METOPROLOL reports
17
Deaths
30
Hospitalizations
How Dangerous Is Second primary malignancy From METOPROLOL?
Of the 42 reports, 17 (40.5%) resulted in death, 30 (71.4%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for METOPROLOL. However, 42 reports have been filed with the FAERS database.
What Other Side Effects Does METOPROLOL Cause?
Drug ineffective (3,434)
Dyspnoea (3,428)
Dizziness (3,275)
Hypotension (3,213)
Completed suicide (2,959)
Fatigue (2,784)
Off label use (2,580)
Toxicity to various agents (2,404)
Bradycardia (2,024)
Nausea (1,894)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which METOPROLOL Alternatives Have Lower Second primary malignancy Risk?
METOPROLOL vs METRELEPTIN
METOPROLOL vs METRONIDAZOLE
METOPROLOL vs METRONIDAZOLE\METRONIDAZOLE
METOPROLOL vs METYRAPONE
METOPROLOL vs MEXILETINE